Dr Ajjai Alva discusses the rationale of pembrolizumab in combination with chemotherapy for the treatment of advanced urothelial cancer and findings from the KEYNOTE-361, and future directions for pembrolizumab research. The late-breaking abstract ‘Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361’ (LBA23) was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020.
- What is the rationale for using pembrolizumab in combination with chemotherapy in the first-line treatment of advanced urothelial cancer? (0:14)
- Could you give us an overview of the aims and design of the KEYNOTE-361 trial? (1:58)
- What were the efficacy and safety findings of this study? (3:40)
- Why do you think the primary endpoint was not met? (5:54)
- How will these findings impact on the role of pembrolizumab in the treatment of advanced urothelial cancer and what future studies involving pembrolizumab in urothelial cancer are planned or are in progress? (8:40)
Speaker Disclosure: Ajjai Alva has been an advisory board member/consultant for Merck Sharp & Dohme Corp, Bristol-Myers Squibb, AstraZeneca, Genentech, Roche, Pfizer, Progenics and Prometheus; has received travel/accommodations/expenses from Merck Sharp Dohmen Corp, Bristol-Myers Squibb and has received research funding through institution from Merck Sharp & Dohme, AstraZeneca, Bristol-Myers Squibb, Astellas, Seattle Genetics, Genentech, Pfizer, Progenics, Prometheus, Eli Lilly, ASCO, Celgene and Harpoon Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. The KEYNOTE-361 trial was sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
Filmed in coverage of the Virtual 2020 ESMO Congress.
PFS = progression-free survival.
Share this Video
Related Videos In Genitourinary Cancer
Axel Merseburger: International Men’s Day and EU Prostate Cancer Day and the Importance of Raising Awareness of Men’s Health and Well-being
Prof Axel S Merseburger (University of Lübeck, Lübeck, Germany), gives his thoughts on the importance of International Men’s Day and EU Prostate Cancer Day in raising awareness of men’s health and well-being. Question International Men’s Day and EU Prostate Cancer Day are both held in November. What is the importance of raising awareness of male […]
Axel S Merseburger, ESMO 2021: Highlights and Key Data in Advanced Prostate Cancer
touchONCOLOGY joins our Editor-in-Chief Prof Axel S Merseburger (University of Lübeck, Lübeck, Germany), to discuss the key data presented at the ESMO Congress 2021 in the field of advanced prostate cancer and the significant impact these advances have on clinical practice. Questions 1. What were the hottest topics and exciting new research from the ESMO […]
Neeraj Agarwal, ESMO 2021: Results of Expanded Cohort 6 of the COSMIC-021 Study
touchONCOLOGY joins Professor Neeraj Agarwal (Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA) at ESMO 2021 to discuss the much-anticipated results of the COSMIC-021 study of cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer. Questions 1. What is the rationale for the combined use of cabozantinib and atezolizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!